under the “short-term deferral” exception. Payments may only be made under the Retention Bonus Letter Agreement upon an event and in a manner permitted by Section 409A of the Code, including the six-month delay for specified employees, or an...Retention Bonus Letter Agreement • March 13th, 2024 • ADC Therapeutics SA • Pharmaceutical preparations
Contract Type FiledMarch 13th, 2024 Company Industry
AMENDMENT TO RETENTION BONUS LETTER AGREEMENTRetention Bonus Letter Agreement • November 14th, 2024 • T2 Biosystems, Inc. • Surgical & medical instruments & apparatus
Contract Type FiledNovember 14th, 2024 Company IndustryThis Amendment to Retention Bonus Letter Agreement is entered into as of November 13, 2024, by and between T2 Biosystems, Inc., a Delaware corporation having its principal place of business at 101 Hartwell Avenue, Lexington, Massachusetts 02421 USA (“T2 Bio”) and John Sprague (“Employee”). Capitalized terms used herein without definition shall have the meaning ascribed thereto in the Retention Bonus Letter Agreement (as defined below).
RETENTION BONUS LETTER AGREEMENT ADDENDUMRetention Bonus Letter Agreement • May 14th, 2003 • Legato Systems Inc • Services-prepackaged software
Contract Type FiledMay 14th, 2003 Company IndustrySubparagraph (iii) of Paragraph A of Part Two of your January 20, 2003 retention bonus letter agreement with the Company contains an incorrect formula for determining your bonus allocation in the event the change in control proceeds payable in connection with an acquisition of Legato Systems, Inc. are more than $ 1 Billion but less than $1.25 Billion. The correct formula is set forth below and replaces and supersedes the formula contained in your retention bonus letter agreement.
AMENDMENT TO RETENTION BONUS LETTER AGREEMENTRetention Bonus Letter Agreement • November 14th, 2024 • T2 Biosystems, Inc. • Surgical & medical instruments & apparatus
Contract Type FiledNovember 14th, 2024 Company IndustryThis Amendment to Retention Bonus Letter Agreement is entered into as of November 13, 2024, by and between T2 Biosystems, Inc., a Delaware corporation having its principal place of business at 101 Hartwell Avenue, Lexington, Massachusetts 02421 USA (“T2 Bio”) and Michael Gibbs (“Employee”). Capitalized terms used herein without definition shall have the meaning ascribed thereto in the Retention Bonus Letter Agreement (as defined below).